DTcP-Hib-MCV4
Phase 1Biologic
CanSino Biologics Inc.DTcP-Hib-MCV4 is one of 35 biologic programs targeting Influenza. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
93 competitors in Influenza
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
FLU Vaccine
GSKPhase 3
Inactivated Influenza Vaccine
SanofiPhase 3
Live Attenuated Zoster Vaccine
CChangchun BCHT Biotechnology Co.
Phase 3
Relenza
GGlaxo Dba Glaxosmithkline
Phase 3
Seasonal Influenza Vaccine
NovartisPhase 3
VAXIGRIP
GSKPhase 3
Dexametasone
UUniversity of Malaya
Phase 3
Baloxavir
IInsight Therapeutics, LLC
Phase 3
GP681
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Influenza1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DTcP-Hib-MCV4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company